Global pharmaceutical company Eli Lilly and Company (NYSE: LLY) announced on Tuesday that it is planning to build a new manufacturing facility at Generation Park in Houston, Texas.
Expected to be operational within five years, the USD6.5bn facility will focus on producing Lilly's pipeline of small molecule medicines across therapeutic areas, including cardiometabolic health, oncology, immunology and neuroscience.
The Houston site will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of 2025.
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
ME Therapeutics secures US patent for lead antibody and advances cancer programmes
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University
Eli Lilly receives US FDA approval for Inluriyo
Biostar Pharma gains FDA orphan drug designation for Utidelone in pancreatic cancer
Hoth Therapeutics expands intellectual property portfolio for HT-001 in US
Lunit partners with CellCarta to expand access to digital pathology AI for clinical trials
Veracyte to present first prospective validation data for prostate cancer biomarker at ASTRO 2025
Eli Lilly plans new manufacturing facility in Houston, Texas
Sichuan Kelun-Biotech Biopharmaceutical NDA for A400 accepted for review in China
Akeso showcasing late-breaking abstract from ivonescimab study at ESMO
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Regenerative Agriculture Pioneer Bob Jones to Deliver Keynote at Metabolic Health Day Conference